EBR Systems Reports Strong Q4 Commercial & Clinical Progress, Preliminary FY25 Revenue

summarizeSummary

EBR Systems reported strong Q4 2025 commercial momentum with doubling implant volumes and initiated two key clinical studies, including one that could significantly expand its market.

check_boxKey Events

• Doubling of WiSE System Implants

  Commercial implant case volumes for the WiSE System doubled in Q4 2025 compared to Q3, with 18 implants during the quarter and 30 total for the pilot and Limited Market Release phases.

• Preliminary Financial Results

  The company expects preliminary unaudited Q4 2025 revenue between US$870K and US$935K, and total 2025 revenue between US$1,552K and US$1,617K.

• Expansion of Commercial Reach

  An additional 9 purchase agreements were signed, and 11 new physicians were trained, expanding the adoption of the WiSE System.

• Commencement of WiSE-UP Study

  The WiSE-UP post-approval study, designed to evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE System, commenced with initial patient enrolments.

auto_awesomeAnalysis

EBR Systems, an emerging growth company, announced significant commercial and clinical advancements for Q4 and full-year 2025. The company reported a doubling of WiSE System implant case volumes in Q4, alongside the commencement of two crucial clinical studies: the WiSE-UP post-approval study and the TLC-AU feasibility study. The TLC-AU study is particularly notable as it aims to evaluate totally leadless CRT in de novo patients, which could substantially expand the company's total addressable market. While preliminary revenues remain modest, these operational and clinical milestones indicate strong progress in product adoption and future market expansion, which are critical for an early-stage medical device company.